Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study

Journal of Allergy and Clinical Immunology

Volumn 100, Issue 4, 1997, Pages 527-535

  Gantner, Florian ^a   Tenor, Hermann ^a   Gekeler, Volker ^a   Schudt, Christian ^a   Wendel, Albrecht ^b   Hatzelmann, Armin ^a  

^a ALTANA PHARMA AG   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Atopic dermatitis; Cyclic 3'5' adenosine monophosphate; Phosphodiesterase 4 subtyes; Phosphodiesterases; Rolipram; RS 25344; T cell proliferation; Tumor necrosis factor ; Zardaverine

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHYTOHEMAGGLUTININ; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; ZARDAVERINE;

ARTICLE; ATOPY; B LYMPHOCYTE; BLOOD DONOR; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; HUMAN; HUMAN CELL; LEUKOCYTE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030876492     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(97)70146-5     Document Type: Article

References (46)

1. Torphy TJ, Murray KJ, Arch JRS. Selective phosphodiesterase isozyme inhibitors. In: Page CP, Metzger WJ, editors. Advances in clinical pharmacology: drugs and the lung. New York: Raven Press, 1994:397-447.
2. Palfreyman MN. Phosphodiesterase type IV inhibitors as antiinflammatory agents. Drugs Future 1995;20:793-804.
3. Dent G, Giembycz MA. Interaction of PDE4 inhibitors with enzymes and cell functions. In: Schudt C, Dent G, Rabe KF, editors. Phosphodiesterase inhibitors. London: Academic Press, 1996:115-9.
4. Grewe SE, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP phosphodiesterase in atopic disease: a possible mechanism for cAMP hyporesponsiveness. J Allergy Clin Immunol 1982;70:452-7.
5. Holden CA, Chan SC, Hanifin JM. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 1986;87:372-6.
6. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993;91:1179-88.
7. Elliot ST, Hanifin JM. Lymphocyte response to phytohemagglutinin in atopic dermatitis. Enhancement after in vitro culture. Arch Dermatol 1979;115:1424-6.
8. Jakob T, Huspith BN, Latchman YE, Rycroft R, Brostoff J. Depressed lymphocyte transformation and the role of prostaglandins in atopic dermatitis. Clin Exp Immunol 1990;79:380-4.
9. 2 control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis. J Allergy Clin Immunol 1996;97:85-94.
10. Banner KH, Roberts NM, Page CP. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995;116:3169-74.
11. Conti M, Jin S-LC, Monaco L, Repaske DR, Swinnen JV. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr Rev 1991;12:218-34.
12. Sette C, Iona S, Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 1994;269:9245-52.
13. Sette C, Vicini E, Conti M. The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J Biol Chem 1994;269:18271-4.
14. Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER, et al. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 1995;48:616-22.
15. Manning CD, McLaughlin MM, Livi GP, Cielinski B, Torphy TJ, Barnette M. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol Exp Ther 1996;276:810-8.
16. 2. J Biol Chem 1995;270:23598-604.
17. Torphy TJ, Zhou H-L, Cieslinski LB. Stimulation of beta adrenoceptors in a human monocytic cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase. J Pharmacol Exp Ther 1992;263:1195-1205.
18. Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin S-LC. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 1995;47:1164-71.
19. Hatzelmann A, Tenor H, Schudt C. Differential effect of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995;114:821-31.
20. Thompson WJ, Appleman MM. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cycl Nucl Res 1979;10:69-92.
21. Bauer AC, Schwabe U. An improved assay of cyclic 3′, 5′-nucleotide phosphodiesterase with QAE Sephadex A-25. Naunyn Schmiedebergs Arch Pharmacol 1980;311:193-8.
22. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995;25:625-33.
23. Wilisch A, Noller A, Handgretinger R, Weger S, Nussler V, Niethammer D, et al. Mdr1/P-glycoprotein expression in natural killer (NK) cells enriched from peripheral or umbilical cord blood. Cancer Lett 1993;69:139-48.
24. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995;89:356-63.
25. Engels P, Fichtel K, Lübbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett 1994;350:291-5.
26. Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, Mulkin M, et al. The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 1993;129:239-47.
27. Jung HC, Eckmann L, Yang S-K, Panja A, Fierer J, Morzycka-Wroblewska, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995;95:55-65.
28. Chan SC, Hanifin JM. Differential inhibitor effect on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:44-51.
29. Alvarez R, Wilhelm R, Shelton ER, Daniels DV, Yang D, Kelly K, et al. Potent and selective inhibition of cyclic AMP specific phosphodiesterase (PDE IV) by structural analogs of nitraquazone. Can J Physiol Pharmacol 1994;72(Suppl 1):510.
30. Engels P, Sullivan M, Müller T, Lübbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett 1995;358:305-10.
31. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58.
32. Rivier A, Pène J, Rabesandratana H, Chanez F, Bousquet J, Campbell AM. Blood monocytes of untreated asthmatics exhibit some features of tissue macrophages. Clin Exp Immunol 1995;100:314-8.
33. + blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993;23:2053-8.
34. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors. Br J Pharmacol 1997;121:221-31.
35. Essayan DM, Huang S-K, Undem BJ, Kagey-Sobotka A, Lichtenstein LM. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994;153:3408-16.
36. Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993;100:681-4.
37. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996;31:23-35.
38. Gantner F, Schudt C, Wendel A, Hatzelmann A. Synergistic inhibition of human T cell proliferation by PDE III and PDE IV inhibitors. Inflamm Res 1995;44:264.
39. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58.
40. 2 regulation of cytokine production in atopic dermatitis. J Immunol 1993;151:3345-52.
41. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995;105:84S-8S.
42. + T lymphocytes. Clin Exp Allergy 1995;25:616-24.
43. Robiscek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB. Multiple high-affinity cyclic AMP phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 1991;42:869-77.
44. Goldberg BJ, Lad PM, Ghekiere L. Phosphodiesterase activity and superoxide production in normal and asthmatic subjects neutrophils. J Allergy Clin Immunol 1994;93:166.
45. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.
46. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.